Halozyme Therapeutics, Inc. (BMV:HALO)

Market Cap	141.05B -2.2%
Revenue (ttm)	27.19B +39.1%
Net Income	6.29B -28.1%
EPS	51.21 -24.4%
Shares Out	n/a
PE Ratio	22.43
Forward PE	7.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400
Average Volume	1,161
Open	1,191.00
Previous Close	n/a
Day's Range	1,191.00 - 1,192.50
52-Week Range	954.15 - 1,395.66
Beta	n/a
RSI	53.70
Earnings Date	May 11, 2026

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 423
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: HALO

Financial Performance

In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.

Financial numbers in USD